Market Place
Sourcing Support
Ascentage Pharma’s Lisaftoclax NDA Accepted for Review in China
17 Nov 2024 //
PR NEWSWIRE
ASH 2024: Olverembatinib Data Selected for Oral Presentation
06 Nov 2024 //
PR NEWSWIRE
ASH 2024: Ascentage Pharma`s Lisaftoclax Data to Be Presented
06 Nov 2024 //
PR NEWSWIRE
Ascentage Pharma Releases Olverembatinib Data In SDH-Deficient GIST
13 Sep 2024 //
PR NEWSWIRE
Ascentage To Present Olverembatinib Data In SDH-Deficient GIST At ESMO
08 Sep 2024 //
PR NEWSWIRE
Ascentage Pharma Announces 2024 Interim Results
22 Aug 2024 //
PR NEWSWIRE
China CDE Clears Phase III Study Of Lisaftoclax For Myelodysplastic Syndrome
12 Aug 2024 //
PR NEWSWIRE
Olverembatinib Approved for Commercialization in Macau China
07 Jul 2024 //
PR NEWSWIRE
Ascentage Pharma Received US$100 Million Option Payment from Takeda
03 Jul 2024 //
PR NEWSWIRE
Ascentage Pharma Submits Draft Registration for Proposed IPO of ADS
23 Jun 2024 //
PR NEWSWIRE
Ascentage Pharma Announces Closing of US$75 Million Equity Investment by Takeda
20 Jun 2024 //
PR NEWSWIRE
EHA 2024: Olverembatinib Studies Show Encouraging Data In CML And Ph+ ALL
18 Jun 2024 //
PR NEWSWIRE
Ascentage Releases Lisaftoclax Data At EHA Showing Improvement In Amyloidosis
18 Jun 2024 //
PR NEWSWIRE
Takeda circles Ascentage`s Scemblix challenger for up to $1.3B
15 Jun 2024 //
FIERCE PHARMA
Takeda Signs Option With Ascentage For Olverembatinib License
14 Jun 2024 //
BUSINESSWIRE
Ascentage Signs Option With Takeda For Olverembatinib License
14 Jun 2024 //
PR NEWSWIRE
China NMPA approves Ascentage Pharma’s phase III study of olverembatinib
12 Jun 2024 //
PHARMABIZ
China Approves Phase 3 Trial Of Olverembatinib For SDH-Deficient GIST
10 Jun 2024 //
PR NEWSWIRE
Olverembatinib: 92.3% CBR In SDH-Deficient GIST Per ASCO 2024 Report
04 Jun 2024 //
PR NEWSWIRE
Ascentage Pharma: Lisaftoclax Safety/Efficacy Data In Waldenstrom`s Cancer
04 Jun 2024 //
PR NEWSWIRE
Updated Lisaftoclax/Azacitidine AML Data Show Efficacy, Manageable Safety
04 Jun 2024 //
PR NEWSWIRE
Ascentage`s FAK/ALK/ROS1 Inhibitor APG-2449 Updated NSCLC Data At ASCO
01 Jun 2024 //
PR NEWSWIRE
Ascentage releases latest results from multiple clinical studies of lead drug
25 May 2024 //
INDIANPHARMAPOST
Ascentage Pharma Asco 2024: Multiple Candidate Clinical Study Updates
23 May 2024 //
PR NEWSWIRE
EHA 2024: Five Ascentage Pharma Studies Selected For Presentations
15 May 2024 //
PR NEWSWIRE
Ascentage Presents 4 Studies, Olverembatinib GIST Data at ASCO 2024
24 Apr 2024 //
PR NEWSWIRE
Ascentage Pharma Announces 2023 Annual Results
27 Mar 2024 //
PR NEWSWIRE
AACR 2024 | Ascentage Pharma to Present Three Preclinical Studies
05 Mar 2024 //
PR NEWSWIRE
Global Registrational Phase III Study of Olverembatinib Cleared by FDA
13 Feb 2024 //
PR NEWSWIRE
Olverembatinib Included in Newest Guidelines on CML Management from NCCN
16 Jan 2024 //
PR NEWSWIRE
Ascentage Pharma Presented at 42nd Annual J.P. Morgan Healthcare Conference
10 Jan 2024 //
PR NEWSWIRE
Ascentage Pharma to Present at 42nd J.P. Morgan Healthcare Conference
01 Jan 2024 //
PR NEWSWIRE
Oral Report Featuring Data of Olverembatinib in Patients with Ph+ ALL Presented
14 Dec 2023 //
PR NEWSWIRE
Results from Studies of Olverembatinib Presented in Oral Report at the ASH
13 Dec 2023 //
PR NEWSWIRE
Ascentage Pharma Presents Updated Data from US Study of Olverembatinib
11 Dec 2023 //
PR NEWSWIRE
Ascentage Releases Encouraging Long-Term Data of Bcl-2 Inhibitor Lisaftoclax
11 Dec 2023 //
PR NEWSWIRE
Ascentage Pharma Presents the First Dataset of Bcl-2 inhibitor Lisaftoclax
11 Dec 2023 //
PR NEWSWIRE
Ascentage Pharma Hosts Ceremony Marking the Launch of Olverembatinib
24 Nov 2023 //
PR NEWSWIRE
Ascentage to Present Results from Three Studies of Bcl-2 Inhibitor Lisaftoclax
02 Nov 2023 //
PR NEWSWIRE
First Patient Dosed in the Registrational Phase III Study of Olverembatinib
17 Oct 2023 //
PR NEWSWIRE
Ascentage Pharma and AstraZeneca Enter into Clinical Collaboration
15 Oct 2023 //
PR NEWSWIRE
Ascentage Pharma Announces 2023 Interim Results
21 Aug 2023 //
PR NEWSWIRE
Ascentage Received Clearance from FDA to Proceed with PIII Trial for Lisaftoclax
06 Aug 2023 //
PR NEWSWIRE
Registrational Pivotal PhIII Study of Olverembatinib for First-Line Treatment
06 Jul 2023 //
PR NEWSWIRE
Registrational PIII Study of Olverembatinib for First-Line Treatment of Ph+ ALL
05 Jul 2023 //
PR NEWSWIRE
Ascentage Pharma Releases Updated Data Showing APG-2449`s Potential
06 Jun 2023 //
PR NEWSWIRE
Ascentage `s Novel Drug Olverembatinib Recommended for a Breakthrough Therapy
30 May 2023 //
PR NEWSWIRE
Antengene To Present Latest Results from TORCH-2 Study of ATG-008
25 May 2023 //
PR NEWSWIRE
Ascentage Pharma Presents Updated Results from Multiple Clinical Studies
25 May 2023 //
PR NEWSWIRE
Ascentage Pharma to Present Results from 4 Studies Highlighting
27 Apr 2023 //
PR NEWSWIRE
Ascentage Passes GMP Compliance Audit by EU QP with Zero Deficiency
24 Apr 2023 //
PR NEWSWIRE
Ascentage Announces Annual Results Including Strong Sales of Olverembatinib
22 Mar 2023 //
PR NEWSWIRE
Ascentage Pharma to Present Latest Results from Three Preclinical Studies
14 Mar 2023 //
PR NEWSWIRE
Olverembatinib Included into the 2022 National Reimbursement Drug List
18 Jan 2023 //
PR NEWSWIRE
Ascentage Pharma Delivers Oral Report on the First Dataset from HQP1351
11 Dec 2022 //
PRNEWSWIRE
Ascentage Announces IND Approval in China for Phase I Study of APG-5918
10 Nov 2022 //
PRNEWSWIRE
China NMPA grants IND clearance for Ascentage’s cancer trial
10 Nov 2022 //
CLINICALTRIALSARENA
Ascentage to Present Data of Olverembatinib in Three Oral Reports
03 Nov 2022 //
PRNEWSWIRE
Ascentage to Present Data of Bcl-2 Inhibitor Lisaftoclax with BTK Inhibitors
03 Nov 2022 //
PRNEWSWIRE
Ascentage Pharma to Announce Results from IAP Antagonist APG-1387
19 Oct 2022 //
PRNEWSWIRE
